FOR IMMEDIATE RELEASE

Prokaryotics Announces Licensing Agreement with Merck for
Novel Investigational Antibiotic Candidates

Union, NJ — January 25, 2018 — Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Merck, known as MSD outside the United States and Canada.

As part of this agreement, Prokaryotics gains worldwide rights to develop, manufacture and commercialize a collection of early pre-clinical programs and compounds with potential application as novel antibiotics targeting Gram-negative and Gram-positive bacterial cell envelope enzymes.  Specific terms of the agreement were not disclosed.

“As a leader in antibiotics research and development we are grateful for Merck’s support in the formation of Prokaryotics and sharing our vision in providing innovation in the field of antibiotic R&D and commitment to addressing the global threat of antibiotic resistance,” said Terry Roemer, PhD, Founder and CSO.

“By bringing together this exciting portfolio of assets along with our internationally renowned network of academic experts and collaborators, Prokaryotics is well positioned to translate these assets into the much-needed next generation of antibiotics with novel mechanisms.”

Prokaryotics is located at the Institute for Life Science Entrepreneurship (ILSE), at Kean University, in Union, New Jersey.  Keith Bostian, PhD, CEO of ILSE, and Interim CEO of Prokaryotics, said, “As a start-up company, Prokaryotics has an impressive array of assets to contribute to the global efforts in combating antimicrobial resistant bacteria (AMR), and we are very pleased to have them in ILSE’s base of partner companies focused on this major unmet medical need. Companies with truly innovative strategies to counter the epidemic of AMR bacteria are critically important.”

About Multi-Drug Resistant Infections

The relentless advance of antibiotic drug resistant bacteria has raised concerns whether within the next 2-3 decades we could be facing a ‘pre-antibiotic era’ – where existing antibiotics will become largely ineffective in treating serious and life-threatening infections. Indeed, the World Health Organization has projected that the impact on human health and economic costs associated with antibiotic drug resistance will rival that of global warming. New classes of antibiotics with novel mechanisms of action are urgently needed to combat the growing threat of multi-drug resistant bacteria.

About Prokaryotics, Inc.

Prokaryotics, Inc. is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes that target serious multi-drug resistant bacterial infections. Prokaryotics, Inc. leverages a deep knowledge of bacterial physiology, innovative screening strategies, and scientific excellence necessary to discover and develop new classes of antibiotics targeting outer membrane biogenesis – the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics.

Contact: Pamela Demain
Phone: 908 737-1922 x120
Email: pdemain@prokaryotics.com